Aktis Oncology Inc AKTS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Aktis Oncology Reports Third-Quarter Financial Results and Highlights Clinical Trial Progress
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
Aktis Oncology to Present at Upcoming September Investor Conferences
Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment
Trading Information
- Previous Close Price
- $16.28
- Day Range
- $15.76–16.73
- 52-Week Range
- $13.96–34.19
- Bid/Ask
- $15.68 / $17.77
- Shares Outstanding
- 55.80M
- Market Cap
- $924.40M
- Volume/Avg
- 244,550 / 383,515
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 71.74
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 79
Valuation
Metric | AKTS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.90 |
Price/Sales | 71.74 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | AKTS |
|---|---|
Quick Ratio | 16.10 |
Current Ratio | 16.33 |
Interest Coverage | — |
Quick Ratio
AKTS
Profitability
Metric | AKTS |
|---|---|
Return on Assets (Normalized) | −15.38% |
Return on Equity (Normalized) | −36.23% |
Return on Invested Capital (Normalized) | −41.44% |
Return on Assets
AKTS
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|rRWgt>$ | LOCK|@Z?N | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|l^lq@! | LOCK|ZG?#y | $99B | |||
| Moderna Inc MRNA | LOCK|V?DPMZ | LOCK|R<q | $90B | |||
| argenx SE ADR ARGX | LOCK|#ClVLjF | LOCK|&N? | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|m!<d%& | LOCK|V?z | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|T?n%Rkpf | LOCK|m?jXl | $31B | |||
| Incyte Corp INCY | LOCK|>V<N>!W | LOCK|@& | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|KW!?>Q | LOCK|yh#H | $22B | |||
| BioNTech SE ADR BNTX | LOCK|YR<!sY | LOCK|S%P | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|%@^Q&W | LOCK|fM | $16B |
United States